Eli Lilly to acquire Loxo Oncology for $8 billion Medical Dialogues Bureau8 Jan 2019 12:09 PM ISTWashington: -Pharmaceutical giant Eli Lilly will acquire cancer treatment specialist Loxo Oncology in a cash deal valued at around $8 billion, the...
SGLT2 inhibitors can lead to serious genital infection: USFDA warning Ruby Khatun Khatun31 Aug 2018 4:50 PM ISTThe SGLT2 inhibitors approved by the FDA include Johnson and Johnson's Invokana, Eli Lilly & Co's Jardiance, as well as those from Bristol-Myers...
Roche drug cocktail doubles chance of holding lung cancer at bay Ruby Khatun Khatun9 Dec 2017 9:45 AM ISTZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTZURICH: Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sept 2017 9:25 AM ISTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
Novartis posts a win, Roche a flop in skin cancer trials Ruby Khatun Khatun12 Sept 2017 12:30 PM ISTZURICH/MADRID: Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sept 2017 9:15 AM ISTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
Bristol-Myers stops kidney cancer drug test after early success Ruby Khatun Khatun11 Sept 2017 10:48 AM ISTBristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end...
